KCNT1 and epilepsy: Unfortunately, after over 10 years of research efforts, KCNT1-related epilepsies remain highly refractory to current anti-seizure medications (Bonardi et al., 2021); thus, a better understanding of the pathological mechanisms underlying KCNT1-related epilepsies—from mutated gene to altered K+ current to altered neuronal physiology to altered neural network to seizure—is imperative for advancing therapeutic strategies to improve seizure control and enhance patient quality of life.